EMEA confirms withdrawal recommendation for dextropropoxyphene
This article was originally published in SRA
Executive Summary
The European Medicines Agency has recommended that all non-parenteral forms of medicines containing the analgesic dextropropoxyphene be withdrawn because their risks – particularly the possibility of fatal overdose – outweigh their benefits1.
You may also be interested in...
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
EU Parliament Urges Post-Brexit Cooperation
Life science companies will be pleased to hear that the European Parliament is pressing for close cooperation between the UK and the EU in the area of medicines regulation.
EU Parliament Urges Post-Brexit Cooperation On Medicines
Life science companies will be pleased to hear that the European Parliament is pressing for close cooperation between the UK and the EU in the area of medicines regulation.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: